TABLE A1.
Patient Characteristics—Enrolled Patients With mUC
| Characteristic | All (n = 39) |
|---|---|
| Median age, years (range) | 61 (42-82) |
| Sex, No. (%) | |
| Male | 30 (76.1) |
| Female | 9 (23.1) |
| Race, No. (%) | |
| White | 35 (89.7) |
| Black or African American | 1 (2.6) |
| Asian | 3 (7.7) |
| Tumor location, No. (%) | |
| Lower tract (bladder, urethra) | 28 (71.8) |
| Upper tract (ureter/renal pelvis) | 11 (28.2) |
| Karnofsky performance status, %, No. (%) | |
| 90 | 20 (51.3) |
| 80 | 13 (33.3) |
| 70 | 6 (15.4) |
| Bajorin risk score, No. (%) | |
| 0 | 12 (30.8) |
| 1 | 21 (53.8) |
| 2 | 5 (12.8) |
| Previous treatments, No. (%)a | |
| Cisplatin | 33 (84.6) |
| Carboplatin | 9 (23.1) |
Abbreviation: mUC, metastatic urothelial carcinoma.
a
All patients with mUC had received platinum-based chemotherapy before enrollment; three patients had received both cisplatin and carboplatin treatments before enrollment.